Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience

This study was done to assess the overall response rate of imatinib mesylate in local patients with chronic myeloid leukaemia. A total of 69 patients were recruited with male/female ratio of 7:3. Of the 69 patients; 35% were in the chronic phase, 41% were in the accelerated phase, 17% were in blast...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical journal of Malaysia 2006-12, Vol.61 (5), p.547
Hauptverfasser:	Bee, P C, Gan, G G, Teh, A, Haris, A R
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Benzamides Cytogenetics Disease Progression Female Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Malaysia Male Piperazines - adverse effects Piperazines - therapeutic use Prognosis Prospective Studies Pyrimidines - adverse effects Pyrimidines - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!